Lexeo Therapeutics, Inc. Common Stock (LXEO)
LXEO Stock Price Chart
Explore Lexeo Therapeutics, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze LXEO price movements and trends.
LXEO Company Profile
Discover essential business fundamentals and corporate details for Lexeo Therapeutics, Inc. Common Stock (LXEO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Nov 2023
Employees
75.00
Website
https://www.lexeotx.comCEO
R. Nolan Townsend
Description
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
LXEO Financial Timeline
Browse a chronological timeline of Lexeo Therapeutics, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.30.
Earnings released on 11 May 2026
EPS came in at -$0.25 surpassing the estimated -$0.29 by +13.79%.
Earnings released on 30 Mar 2026
EPS came in at -$0.27 surpassing the estimated -$0.32 by +15.62%.
Earnings released on 5 Nov 2025
EPS came in at -$0.33 surpassing the estimated -$0.48 by +31.25%.
Earnings released on 14 Aug 2025
EPS came in at -$0.60 surpassing the estimated -$0.64 by +6.25%.
Earnings released on 12 May 2025
EPS came in at -$0.99 falling short of the estimated -$0.80 by -23.75%.
Earnings released on 24 Mar 2025
EPS came in at -$0.78 surpassing the estimated -$0.87 by +10.34%.
Earnings released on 13 Nov 2024
EPS came in at -$0.89 falling short of the estimated -$0.65 by -36.92%.
Earnings released on 12 Aug 2024
EPS came in at -$0.64 surpassing the estimated -$0.69 by +7.25%.
Earnings released on 9 May 2024
EPS came in at -$0.77 falling short of the estimated -$0.76 by -1.32%.
Earnings released on 11 Mar 2024
EPS came in at -$0.85 falling short of the estimated -$0.73 by -16.44%.
Earnings released on 6 Nov 2023
EPS came in at -$12.36 falling short of the estimated -$2.60 by -375.38%.
Earnings released on 30 Jun 2023
EPS came in at -$0.53 .
Earnings released on 31 Mar 2023
EPS came in at -$0.74 .
Earnings released on 31 Dec 2022
EPS came in at -$0.59 , while revenue for the quarter reached $654.00k .
Earnings released on 30 Sept 2022
EPS came in at -$0.68 , while revenue for the quarter reached $531.00k .
Earnings released on 30 Jun 2022
EPS came in at -$0.60 , while revenue for the quarter reached $37.00k .
Earnings released on 30 Mar 2022
EPS came in at -$0.47 , while revenue for the quarter reached $85.55k .
LXEO Stock Performance
Access detailed LXEO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
